galmedpharma.com (GLMD) - Koefisien utang jangka dawa marang modal

The price history of Galmed Pharmaceuticals (GLMD) reflects the dynamics of a company developing methods to combat liver pathologies through alliances with global scientific associations. The current separate_debt_long_eq figure is 0.00. The business model remains independent of macroeconomic trends, relying instead on internal drug development cycles. Key growth drivers include patents, the utilization of an IT platform, and clinical trials of the drug Aramchol against steatohepatitis.

This indicator measures the share of long-term liabilities (over one year) relative to equity, determining the issuer's degree of financial autonomy. Investors utilize this ratio to assess bankruptcy risk and the stability of the financing structure. By analyzing the dynamics of long-term loans to equity, the market evaluates the company's margin of safety. For Galmed Pharmaceuticals (GLMD), this balance is critical, as geopolitical sanctions and logistics disruptions are slowing down drug certification. Under such conditions, a low debt load becomes the sole guarantee of survival amid prolonged clinical trials.